XML 62 R51.htm IDEA: XBRL DOCUMENT v3.25.2

Subsequent Events (Details) - Subsequent Event - License agreement - Kaken Pharmaceutical, Co., Ltd $ in Millions	Aug. 06, 2025 USD ($)
Subsequent Events
Receivable license payment	$ 16.0
Commercialization and sales milestone	$ 16.0
Percentage royalty rate	30.00%
Royalty payments term	10 years
Termination license agreement	30 days
Termination license agreement period	90 days

X

- Definition

Number of days notice pursuant to termination of agreement.

+ References

No definition available.

+ Details

Name:	atxs_AgreementTerminationNoticePeriod
Namespace Prefix:	atxs_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Number of days notice for material safety issue pursuant to termination of agreement.

+ References

No definition available.

+ Details

Name:	atxs_AgreementTerminationNoticePeriodForMaterialSafetyIssue
Namespace Prefix:	atxs_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Amount of additional commercialization and sales milestone payment receivable under the agreement.

+ References

No definition available.

+ Details

Name:	atxs_CommercializationAndSalesMilestonePaymentReceivable
Namespace Prefix:	atxs_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

X

- Definition

Denotes the duration of royalty payments from the first commercial sale of the product.

+ References

No definition available.

+ Details

Name:	atxs_RoyaltyPaymentsTermFromFirstCommercialSale
Namespace Prefix:	atxs_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

X

- Definition

The maximum royalties to be received as a percentage of net sales.

+ References

No definition available.

+ Details

Name:	atxs_TieredRoyaltiesPercentageOfNetSalesMaximum
Namespace Prefix:	atxs_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	instant

X

- Definition

Amount of upfront license fees to be received.

+ References

No definition available.

+ Details

Name:	atxs_UpfrontLicensePaymentReceivable
Namespace Prefix:	atxs_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

X

- Definition

Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 830
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481674/830-30-50-2

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 855
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483399/855-10-50-2

+ Details

Name:	us-gaap_SubsequentEventLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Details

Name:	us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=atxs_LicenseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_CounterpartyNameAxis=atxs_KakenPharmaceuticalCo.LtdMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: